Abstract
IntroductionThe direction of the causal link between solid cancers and elevated plasma vitamin B12 (B12) remains uncertain.MethodsWe retrospectively included patients having two B12 measurements with a B12 initially ≥ 1000 ng/l and a solid cancer diagnosed between the measurements. Patients were included in the Curative or Supportive group according to their treatments.ResultsB12 changes over time differed between groups (p = 0.001): +157.4 ng/l/month in the Supportive care group versus –171.6 ng/l/month in the Curative care group.ConclusionsThe decrease of plasma B12 in cases of curative care could suggest that this B12 elevation is secondary to solid cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
